Danaher, AstraZeneca partner on AI diagnostics for precision medicine

USA – Danaher Corporation has announced a strategic partnership with AstraZeneca to develop and commercialize advanced diagnostic tools that support precision medicine.

This collaboration aims to assist clinicians in accurately identifying patients who are most likely to benefit from targeted therapies.

The partnership will utilize the newly established Danaher Centers for Enabling Precision Medicine to streamline the development process.

The first product emerging from this alliance will incorporate technologies from Danaher’s subsidiary, Leica Biosystems, focusing on computational pathology, digital diagnostics, and AI-powered algorithms to improve disease detection and patient selection.

Leica Biosystems, recognized for its digital pathology innovations, is scaling its solutions for clinical use across its global laboratory network.

To enhance efficiency and interoperability, Leica is adopting the open-access DICOM standard for digital imaging and communication in medicine.

Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, emphasized the importance of diagnostics in delivering next-generation therapies, such as antibody-drug conjugates.

She stated, “Our partnership with Danaher and Leica Biosystems reflects our commitment to advancing AI-based diagnostics, which are key to selecting the right patients for the right treatment.”

Danaher’s expertise in science and technology is pivotal in enabling faster, more accurate diagnoses, while reducing the costs and time involved in drug development and delivery.

This alliance builds upon Danaher’s expanding life sciences portfolio, which includes the August 2023 agreement to acquire UK-based protein consumables provider Abcam in a $5.7 billion deal.